SEC Form 4 · accession 0001171000-15-000049

Nexvet Biopharma plc · NVET

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP Operations, General Counsel

Period of report

Jul 1, 2015

Accepted (ET)

Jul 2, 2015 · 2:17 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001618561

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Ordinary Shares^F1	Jul 1, 2015	M	2,867	$0.125	A	10,758	I	By Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C>
Ordinary Shares	holding	—	—		—	4,300	D
Ordinary Shares^F2	holding	—	—		—	132	I	By Nexvet EBT Limited

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Options to purchase shares^F1,F3	$0.125	Jul 1, 2015	M	2,867	D	Jul 1, 2015	Jul 1, 2019	Ordinary Shares	2,867	10,033	I

F1The reporting person and her spouse share voting and dispositive power with respect to these reported securities.
F2The reporting person has sole voting and dispositive power over the reported securities pursuant to that certain Nominee Deed dated as of 11/14/14 by and between Nexvet EBT Limited and the persons named in the schedule hereto. Such Nominee Deed was executed in connection with the Issuer's November 2014 four-for-five share consolidation.
F32,867 options vested and became exercisable on 7/1/15; a further 2,867 options shall vest and become exercisable on 7/1/16, and 2,866 will vest on 7/1/17. The remaining 4,300 options will vest and be exercisable upon successful completion of an efficacy trial for any Issuer product, as determined by Issuer's board of directors; such completion must occur on or before 7/1/19.